Study on the improvement of therapeutic efficacy of Staphylococcus aureus bacteremia
Not Applicable
- Conditions
- Certain infectious and parasitic diseases
- Registration Number
- KCT0008236
- Lead Sponsor
- Asan Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 338
Inclusion Criteria
1. Adult age over 19 year
2. Confimed MRSA bacteremia
3. Who agree to participate the study
Exclusion Criteria
1. Type 1 hypersensitivity to cefazolin or vancomycin
2. Polymicrobial infection
3. Receiving anti MRSA therapy longer than 72 hours before the study enrollment
4. patient expected to die in the next 48 hour
5. history of MRSA bacteremia within previous 3 months
6. Pregnancy
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 90 days composite outcome with 4 components: (1) all-cause mortality; (2) persistent bacteremia at study day 5; (3) microbiological relapse defined as a positive blood culture for MRSA at least 72 hours after a preceding negative culture; and (4) microbiological treatment failure defined as a positive sterile site culture for MRSA at least 14 days after randomization.
- Secondary Outcome Measures
Name Time Method (1) all-cause mortality; (2) persistent bacteremia at study day 5; (3) microbiological relapse defined as a positive blood culture for MRSA at least 72 hours after a preceding negative culture; and (4) microbiological treatment failure defined as a positive sterile site culture for MRSA at least 14 days after randomization.